Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
2 mg | In stock | $ 68.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 143.00 | |
25 mg | In stock | $ 258.00 | |
50 mg | In stock | $ 369.00 | |
100 mg | In stock | Inquiry | |
1 mL * 10 mM (in DMSO) | In stock | $ 94.00 |
Description | Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions. |
In vitro | TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation inhibited by Setogepram (PBI-4050; 500 μM; 24 hours). Setogepram (PBI-4050; 250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis [2]. |
In vivo | In type 2 diabetes eNOS-/-db/db mice, Setogepram (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improve glucose tolerance [1]. |
Synonyms | PBI-4050, Setogepram |
Molecular Weight | 206.28 |
Formula | C13H18O2 |
CAS No. | 1002101-19-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (290.87 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fezagepras 1002101-19-0 Endocrinology/Hormones GPCR/G Protein GPR PBI 4050 Free Fatty Acid Receptor PBI-4050 GPR84 inhibit PBI4050 FFAR G protein coupled receptor 84 Diabetes,Kidney,Renal,Pancreatic,Liver,Fibrosis,Nephrology Inhibitor Setogepram inhibitor